Cara Therapeutics – Hot or Not


Cara Therapeutics (Nasdaq:CARA) is a clinical-stage biopharmaceutical company which also focuses on pain medication. It has a market cap of $455 million, and is not profitable. Guest Devin Shutte from The Robert Group and resident expert Paul Theron from Vestact decide whether Cara Therapeutics is hot or not.

Partner Content

Disruptive digital solutions is rewiring the DNA of Banking

By Kennedy Mubita, Africa Head, SC Ventures. Imagine a bank whose customers can tap on a wearable device to...

The future of banking; digitization and collaboration as growth accelerants

By Kariuki Ngari, CEO & Managing Director, Standard Chartered, Kenya & East Africa COVID-19 has upended the social and...

Star Quality Speaker Line-Up at Africa Tech Festival 2020

Acknowledged as the world’s largest Africa-focused digital infrastructure and emerging tech event, the Africa Tech Festival has always attracted a stellar line-up of critical thinkers, analysts, futurists, keynote and inspirational speakers. 2020 will more than deliver on that reputation, with a stimulating array of visionary industry presenters, raconteurs and even some sporting greats.

Newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox